microdose glp-1 Microdosing GLP-1s: Does It Work? Risks and Benefits Noom Launches GLP-1 Microdosing for

The American Association of Clinical Endocrinology advocates for improved access to these evidence-based therapies, particularly for patients with cardiovascular disease or obesity-related complications where clinical benefits are well-established

doi: 10.1111/dom.15459 [DOI] [PubMed] [Google Scholar] 166.Di Stefano R, Rindi LV, Baldini V, et al

Eligibility criteria for NHS-funded GLP-1 treatment for weight management include: For semaglutide (Wegovy): BMI 35 kg/m (or 32.5 kg/m for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds) with at least one weight-related comorbidity For liraglutide (Saxenda): Similar BMI criteria as defined in NICE TA664 Evidence of previous weight management attempts through lifestyle modification Treatment must be initiated within specialist weight management services (Tier 3) Time-limited use as specified in the relevant NICE guidance The referral pathway typically involves: Initial GP consultation: Discuss weight concerns, document BMI and comorbidities, and review previous weight management efforts Tier 2/3 weight management services: Many areas require participation in structured lifestyle programmes before pharmacological intervention Specialist assessment: Referral to specialist weight management services for treatment initiation Ongoing monitoring: Regular review to assess response, tolerability, and continuation criteria Treatment continuation requires achieving the weight loss thresholds specified in the product-specific NICE guidance and SmPCs

Look at the maximum number printed on the barrel

For guidance on getting started, see our strength training resource for women

If the therapy has been interrupted for a long time, the body is no longer adapted to the physiological changes caused by the medication